Published on 30/11/2025

Governance for PPQ/CPV Across Products

The development of biosimilars entails a comprehensive approach to analytical comparability and the assurance of product quality. A critical component of this process is the effective governance of Product Process Qualification (PPQ) and Continuous Process Verification (CPV). This article serves as a step-by-step tutorial guide aimed at pharmaceutical professionals engaged in clinical operations, regulatory affairs, and medical affairs. It focuses on the establishment of a robust PPQ/CPV strategy for biosimilars, detailing methodologies such as Critical Quality Attribute (CQA) mapping and fingerprint analytics.

Understanding the Fundamentals: What is PPQ and CPV?

Product Process Qualification (PPQ) and Continuous Process Verification (CPV) are essential concepts within the Quality by Design (QbD) framework. The objective of PPQ is to confirm that the manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. CPV complements this by continuously monitoring and verifying the manufacturing process throughout its lifecycle.

According to guidelines such as FDA’s Guidance for Industry on Q8(R2), PPQ consists of evaluating the entire process with rigorous testing coupled with a deep understanding of the various factors that influence product quality. Key aspects include:

• Risk Assessment: Identifying potential risks associated with the manufacturing process and ensuring appropriate controls.
• Process Design: Establishing a robust manufacturing process that adheres to the principles of QbD.
• Control Strategy: Implementing monitoring and measurement systems to continually assess product quality.

Continuous Process Verification entails the ongoing assessment of process data and trends to detect any deviations that may jeopardize product quality. In conjunction with PPQ, CPV provides a holistic oversight of biosimilar production processes. Additionally, relevant European guidelines, such as EMA’s Q6B specifications, emphasize the importance of establishing scientifically sound controls that align with regulatory expectations.

Step-by-Step Process for Developing a PPQ/CPV Strategy

Crafting an effective PPQ/CPV strategy for biosimilars necessitates a systematic approach. This section outlines a step-by-step guide to developing such a strategy, considering the various regulatory frameworks including those of the FDA, EMA, and MHRA.

Step 1: Define Critical Quality Attributes (CQAs)

The first step in forming a robust PPQ/CPV strategy involves determining the Critical Quality Attributes (CQAs) of the biosimilar product. CQAs are physical, chemical, biological, or microbiological properties or characteristics that must be controlled to ensure the product meets its intended safety, efficacy, and quality. For biosimilars, this often involves:

• Identifying the attributes that directly correlate with the product’s performance.
• Mapping the CQAs to ensure they align with both regulatory requirements and patient safety.
• Utilizing historical data and scientific rationale to substantiate CQA selection.

Documentation of this process should be thorough, providing clarity for regulatory agencies during assessments of the submission dossier. The guidelines within ICH Q5E comparability can be a useful reference for establishing these attributes and their evaluation during product development.

Step 2: CQA Mapping and Control Strategy Development

Once CQAs are defined, the next phase involves CQA mapping. This includes the identification of input materials, process parameters, and in-process controls that influence CQAs. This mapping is crucial to understanding how variations within the manufacturing process might affect the quality of the final product.

CQA mapping typically includes:

• Defining correlations between process parameters and CQAs, corroborated with historical data analysis.
• Utilizing design of experiments (DOE) methodologies to proactively establish relationships within the production environment.
• Developing a control strategy that addresses these impacts, thus ensuring consistent product quality.

The documented control strategy should articulate how each identified parameter will be monitored, providing a reference point for ongoing assurance of product quality.

Step 3: Integration of Fingerprint Analytics

Fingerprint analytics represents a powerful approach for measuring the changes in biosimilars during the manufacturing process. By leveraging advanced analytical techniques such as chromatography and mass spectrometry, pharmaceutical companies can track both qualitative and quantitative attributes of the biosimilar product.

Implementation of fingerprint analytics should follow these guidelines:

• Conduct in-depth method development to ensure robustness and reproducibility.
• Utilize statistical analysis methods to determine variations and establish equivalence over time.
• Incorporate this analytical data into the overall CPV framework, enabling real-time monitoring of process drift.

The deployment of such analytics ensures that any significant deviations from the expected product profile are detected early, allowing for timely adjustments to the manufacturing process.

Step 4: Establish Process Drift Monitoring Procedures

Monitoring process drift is a critical aspect of ensuring ongoing product quality. Process drift can occur due to numerous reasons such as changes in raw materials, equipment aging, and environmental factors. An effective process drift monitoring plan involves:

• Defining acceptable ranges for process parameters correlated with CQAs.
• Implementing automated data collection systems for continuous assessment.
• Utilizing control charts and trend analysis to visualize data over time and quickly identify any anomalies.

When anomalies are detected, a thorough investigation should be conducted to assess if the drift poses a risk to product quality. This includes root cause analysis and implementing corrective actions to mitigate any identified risks.

Step 5: Bridging Justifications and Equivalence Testing

As biosimilars aim to replicate the reference product, establishing equivalence is paramount. Bridging justifications and equivalence testing should substantiate that any differences between the biosimilar and the reference product do not impact safety or efficacy. Steps to consider include:

• Conducting head-to-head comparative studies using the defined CQAs.
• Assessing clinical data to demonstrate bioequivalence or therapeutic equivalence as per regulatory requirements.
• Preparing comprehensive documentation that justifies all conclusions drawn regarding equivalence.

Collaboration with regulatory bodies is crucial at this stage to ensure that all bridge justifications align with FDA and EMA language and expectations.

Regulatory Considerations and Final Dossier Submission

Governance in the context of PPQ and CPV strategies for biosimilars cannot be overstated. A well-structured PPQ/CPV framework not only assures product quality but also facilitates smoother regulatory interactions. Preparing your dossier with a clear narrative that reflects the established governance framework is vital.

Consider the following key elements when preparing the final submission:

• Compliance Documentation: Ensure all protocols, validations, and control measures are documented in compliance with current Good Manufacturing Practice (cGMP) regulations.
• Responsive Modifications: Be prepared to address questions or requests for further information from regulatory authorities promptly.
• Post-Market Surveillance: Discuss plans for ongoing monitoring of the biosimilar product post-launch to ensure sustained compliance with quality requirements.

Utilizing frameworks from authorities such as the World Health Organization, along with relevant guidance from EMA and FDA, will enhance your submission’s credibility and ensure a higher likelihood of approval.

Conclusion

Developing a robust governance strategy for PPQ and CPV is paramount in the intricate ecosystem of biosimilar production. By following a structured, methodical approach to defining CQAs, mapping them strategically, and rigorously monitoring process drift, pharmaceutical professionals can ensure that biosimilars meet the stringent quality standards expected by regulatory bodies.

Ensuring alignment with regulatory expectations while implementing sophisticated methodologies like fingerprint analytics will ultimately lead to successful product development and market placement. This step-by-step tutorial serves as a roadmap for professionals striving to navigate the complexities of biosimilar comparability, equipping them with the knowledge necessary to uphold the integrity of the pharmaceutical supply chain.